The Lenalidomide Patch for Myeloma: What Do We Know?

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Dr. Mohamad Hussein previously held a role as Corporate Vice President: Global lead of Multiple Myeloma at Celgene and now currently serves a Board Member and the Hematologic Malignancies Lead at Starton Therapeutics. Dr. Hussein practiced at the Cleveland clinic Foundation, Cleveland, OH for two decades. During his tenure,developed and Directed the multiple myeloma research program at the Cleveland clinic 1996-2006.In January 2006 assumed a position as Professor of Oncology and Medicine, Clinical Director, Malignant Hematology Division, Director of the Myeloma section and Leader, Myeloma Clinical Research at the H Lee Moffitt Cancer Center, and the Univ of South Florida, Tampa FL 2006-2008 and currently Professor of Medicine and Oncology at the University of South Florida, Tampa FL. In August 2008, Dr. Hussein, Joined Celgene Corporation as the VP of Hematology Global Medical Affairs, May 2010 was appointed VP of Americas Medical Affairs,October 2012 VP of Global Scientific Affairs and September 2014 Global Multiple Myeloma Franchise .Dr. Hussein, who is board-certified in medical oncology and internal medicine. He has chaired and conducted over 20 clinical trials resulting in more than 150 published peer-review manuscripts, book chapters, and editorials to his credit.